Invesco Nasdaq Biotech ETFIBBQETF
13F holders, Q2 2024 (June 30)15holders −2
1new positions
1sold out
$18.70avg. 13F price*
At the end of Q2 2024, 15 institutions reported holding Invesco Nasdaq Biotech ETF (IBBQ) in their 13F filings, down 2 from Q1 2024. 1 opened new positions and 1 sold out. The largest holders were Mirae Asset Global Investments Co., Ltd. ($4.8M), Advisory Services Network, LLC ($1.2M) and Raymond James Financial Services Advisors, Inc. ($813K).
- Company
- Invesco Nasdaq Biotech ETF
- CUSIP
- 46138G599
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 1 | $286K |
All 13F filers, Q1 2024 → Q2 2024: 129,369 shares bought and 14,440 shares sold, net +114,929 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Mirae Asset Global Investments Co., Ltd. | 0.02% | No change | 211,596 | $4.8M |
| Advisory Services Network, LLC | 0.02% | Add +3.6% | 50,687 | $1.2M |
| Raymond James Financial Services Advisors, Inc. | 0.00% | Add +14.1% | 35,736 | $813K |
| Knightsbridge Asset Management, LLC | 0.17% | No change | 29,300 | $667K |
| Partners Capital Investment Group, LLP | 0.01% | Add +100.0% | 25,833 | $589K |
| Clarius Group, LLC | 0.03% | Add +0.2% | 19,070 | $434K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +18320.3% | 12,710 | $289K |
| Royal Bank of Canada | 0.00% | Add +229.9% | 12,395 | $282K |
| Bank of Montreal | 0.00% | No change | 3,750 | $87K |
| Bank of America Corp. | 0.00% | No change | 3,691 | $84K |
| WR Wealth Planners, LLC | 0.00% | No change | 685 | $16K |
| Osaic Holdings, Inc. | 0.00% | Reduce -66.3% | 520 | $12K |
| Strategic Financial Concepts, LLC | 0.00% | New | 88,973 | $4K |
| WealthShield Partners, LLC | 0.00% | No change | 100 | $2K |
| Morgan Stanley | 0.00% | Reduce -99.8% | 1 | $34 |
"% of holder's portfolio" is IBBQ's weight in each manager's 13F, not the share of Invesco Nasdaq Biotech ETF the manager owns.